![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Kyowa Hakko Kirin Company, Limited |
---|---|
Information provided by: | Kyowa Hakko Kirin Company, Limited |
ClinicalTrials.gov Identifier: | NCT00364468 |
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.
Condition | Intervention | Phase |
---|---|---|
Neutropenia |
Drug: pegfilgrastim |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma |
Ages Eligible for Study: | 20 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Hokkaido region | |
Hokkaido, Japan | |
Tohoku region | |
Miyagi, Japan | |
Kanto region | |
Gunma, Saitama, Tokyo, Kanagawa, Japan | |
Tokai region | |
Aichi, Japan | |
Kyusyu region | |
Fukuoka, Nagasaki, Japan | |
Kinki region | |
Kyoto, Mie, Shiga, Japan |
Study Chair: | Tomomitsu Hotta, MD | Nagoya Medical Center |
Study ID Numbers: | KRN125/05-A04 |
Study First Received: | August 14, 2006 |
Last Updated: | February 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00364468 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
pegfilgrastim neutropenia cancer patients lymphoma |
Signs and Symptoms Neutropenia Hematologic Diseases Agranulocytosis |
Leukocyte Disorders Leukopenia Granulocytopenia Lymphoma |